Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib

Jain RK, Chen H

Lung Cancer: Targets and Therapy 2017, 8:169-177

Published Date: 13 October 2017